Please ensure Javascript is enabled for purposes of website accessibility

Intuitive Surgical, Inc. Investors Can Breathe a *Qualified* Sigh of Relief

By Brian Stoffel - Apr 5, 2016 at 9:42AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Report backs up the effectiveness of da Vinci in prostatectomies. But you have to read the fine print.

Good news! The daVinci helps drive costs down for prostatectomies. Photo: Intuitive Surgical.

While shareholders of robotic surgery company Intuitive Surgical (ISRG 0.43%) are happy with their stock right now -- up almost 76% since May 2014 and currently flirting with all-time highs -- the story wasn't always so rosy.

Back in 2013, key opinion leaders in gynecology began to raise serious questions about the efficacy and cost-effectiveness of using the da Vinci robot for benign hysterectomy operations. At the time, hysterectomy procedures performed in the U.S. accounted for 37% of all da Vinci procedures worldwide. That skepticism, plus the onset of the Affordable Care Act and the tightening of hospital budgets, caused the stock to lose over 35% of its value in just six months' time.

Fast-forward to the present
Today, those benign hysterectomy procedures have stabilized and been replaced with growth elsewhere -- some of that coming from prostatectomies. During 2015, there were 145,000 prostatectomy procedures worldwide performed using da Vinci -- 22% of all da Vinci procedures for the year. That means that continually proving the cost-effectiveness of the robot in prostatectomies is paramount to the company and its shareholders.

A report released just last week by Dr. Ashutosh Tewari of New York's Mount Sinai Health System should give investors some comfort. Dr. Tewari wanted to investigate the cost-savings associated with using robotic-assisted Laparoscopic Prostatectomies over more the more traditional methods (technically, Retropubic Radical Prostatectomy). Tewari wanted to measure potential cost-savings on three dimensions: for the hospital, for patients or their insurance companies, and for society at large.

What he found was largely encouraging:

  • 99% of the time, the payers themselves saved money, at an average of $1,451 per procedure.
  • 83% of the time, society's costs were lower thanks to da Vinci, with an average savings of $1,202 per procedure.

When it came to hospital costs, the results were more mixed. Dr. Tewari reported that between 38% and 79% of the time, hospitals saved money thanks to the da Vinci. When calculated on the basis of overhead costs, inpatient bed, and inpatient days, hospitals saved $1,094 per procedure. However, when calculated on the basis of the annual volume of robotic procedures, hospitals lost roughly $341 more than they would have if they used more traditional techniques.

Commenting on the discrepancy, Dr. Myriam Curet, Intuitive's chief medical officer, said, "This study further demonstrates that hospital administrators need to look beyond visible operating room costs when analyzing the robotic-assisted surgery value proposition. The ability of robotic-assisted surgery to reduce complications and shorten hospital stays undoubtedly leads to greater value for patients and healthcare providers."

There's always a catch
But investors shouldn't get too giddy over the results -- which seem to paint a glowing picture of da Vinci. At the end of the report, it specifies that "Intuitive Surgical provided funding for independent research and editorial support," and that "Dr. Ashutosh Tewari receives financial compensation as a lecturer from Intuitive Surgical."

While I -- as an Intuitive shareholder -- am glad to see such positive results, I'm not going to read too much into them. The most damning -- and supportive -- findings usually come from third parties that have no financial interests in the players involved.

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intuitive Surgical, Inc. Stock Quote
Intuitive Surgical, Inc.
ISRG
$219.07 (0.43%) $0.93

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.